GPT and metabolic syndrome: Fouret et al. and Fink et al. presented MitoQ as an intervention that not only improved metabolic syndrome features but also prevented weight gain and hepatic dysfunction, markedly reduced hepatic lipid hydroperoxides and reduced circulating alanine aminotransferase, as well as decreased pathogenic alterations to cardiolipin content and profiles in rodents (17, 23–25).